AccuDava

Executive Summary

AccuDava is a San Diego-based biotechnology company founded in 2017, focused on addressing platinum chemotherapy resistance in cancer. The company's dual platform combines a diagnostic test to identify patients unlikely to respond to standard platinum-based drugs before treatment, thus sparing them from ineffective toxicity, with a complementary therapeutic approach designed to overcome this resistance. By targeting a critical unmet need in oncology, AccuDava aims to improve patient outcomes and enable personalized treatment strategies for a broad range of cancers where platinum agents are commonly used. The company is privately held and operates in the diagnostics and therapeutics space, leveraging its proprietary insights into the mechanisms of chemoresistance. Given the prevalence of platinum-based chemotherapy in first-line settings, AccuDava's solutions have potential across multiple tumor types, including ovarian, lung, and head and neck cancers. The diagnostic could reduce unnecessary side effects and healthcare costs by steering non-responders toward alternative therapies earlier. Meanwhile, the therapeutic candidate offers a novel mechanism to resensitize tumors to platinum agents. While still in early development, the company's focused approach and clear value proposition position it as an attractive candidate for partnership or further investment. Success in preclinical validation and clinical trials could drive significant adoption, though the technology remains unproven in late-stage studies.

Upcoming Catalysts (preview)

• Q3 2026Publication of validation data for platinum resistance diagnostic test60% success
• Q1 2027IND filing for therapeutic candidate40% success
• Q4 2026Strategic partnership with diagnostics or pharma company50% success